International Society for Pharmacoeconomics and Outcomes Research

1. International Society for Pharmacoeconomics and Outcomes Research

2. Chris L Pashos, PhD ISPOR President, 2008-2009

3. ISPOR SRBIJA

4. Belgrade, Serbia

5. WELCOMEDOBRODOšLIISPOR SRBIJA 1ST INTERNATIONAL CONFERENCE

6. President Vladimir Zah, K.S. B.Sc., Health Economics Consultant, Belgrade Vice-President Tanja Novakovic, MSc Pharm., Galenika a.d., President of Pharmacoeconomic Section of Pharmaceutical Society of Serbia (FDS), Belgrade Secretary / Treasurer Dr sci. ph. spec Natasa Bogavac-Stanojevic, Assoc. Professor, Faculty of Pharmacy, University of Belgrade

7. Directors Dr sci. med. Ana Sabo, Professor, Medical Faculty, University of Novi Sad Dr Predrag Djukic, Consultant, Project Coordination Unit, Ministry of Health, Belgrade Dr Dragana Atanasijevic, ConsultantProject Coordination Unit, Ministry of Health, Belgrade Doc.dr sci.ph Vesela Radonjic, Director, National Information Center for Medicine and Medical Devices (ALIMS), Belgrade Mr ph Danka Stefanovic, ALIMS, Belgrade Mr ph Danka Tesic, ALIMS, Belgrade Mr ph spec. Dragana Sovtic, Independent advisor for pharmaceutical issues, The Pharmaceutical Chamber of Serbia

8. ISPOR An international, educational and scientific organization that fosters excellence in pharmacoeconomics and outcomes research and the appropriate use of resulting information in health care decisions at all levels to promote the public health and well-being

9. OUR MISSION To promote the science of pharmacoeconomics and outcomes research To facilitate the translation of this research into useful information for health care decision makers To ensure that society allocates scarce resources wisely, fairly, and efficiently RESEARCHEVIDENCEDECISIONSHEALTH

10. Who we are • Where we are going • How we will get there

11. OUR SCOPE MULTI-DISCIPLINARY Decision Analysis, Economics, Epidemiology, Modeling, Patient Reported Outcomes Assessment, Real World Data Analysis, Risk Assessment INCLUSIVE Decision Makers, Health Care Providers, Researchers, Students GEOGRAPHICALLY DIVERSE

12. Over 4200 members From 96 countries Who We Are

13. STUDENT NETWORK Who We Are 40Student Chapters Worldwide 484Student Members

14. Who We Are ISPOR Membership Including Chapters

15. ISPOR Membership including Chapters Who We Are 2400 ISPOR CHAPTER MEMBERS 4200 ISPOR MEMBERS OVER 6600 WORLDWIDE

16. Who We Are Asia-Pacific • China MDA-PE • Hong Kong • India • Japan • Shanghai • Taiwan • Thailand • Australia • Under development • Malaysia • South Korea • Pakistan • Singapore

17. Who We Are Latin America • Argentina • Brazil • Chile • Colombia • Mexico • Venezuela • Under development • Cuba • Ecuador • Peru

18. Who We Are Europe – Middle East • Belarus • Croatia • Czech Republic • Greece • Hungary • Poland • Russia • Serbia • Slovakia • Turkey • Ukraine • Israel • Jordan

19. MEMBERSHIP by Geographic Region Who We Are

20. MEMBERSHIP by Work Environment Who We Are

21. Who We Are MEMBERSHIP - WORK ENVIRONMENT Academia Research Groups Health Care Providers Medical Technology Firms Governments

22. MEMBERSHIP by Research Interests Who We Are

23. Who We Are MEMBERSHIP – RESEARCH INTERESTS Methods PROs Costs Clinical Outcomes Policy

24. Who We Are ISPOR – MOVING AHEAD TOGETHER

25. Where We Are Going Patients (Recipients of Health Care) Patients Health Care Providers FOSTER RESEARCH EXCELLENCE PROMOTE EDUCATION Health Care Payers Health Care Health Care Researchers PROMOTE COLLABORATION WITH DECISION MAKERS STIMULATE INTERNATIONAL GROWTH Regulators & Tech Assessors

26. What We Do GLOBAL OUTREACH

27. Athens, Greece - November 2008

28. MEETINGS IN EUROPE What We Do

29. What We Do MEETING REGISTRATION: EUROPE

30. II. Medzinárodná konferencia ISPOR Slovak Chapter Zastúpenie Medzinárodnej spoločnosti pre farmakoekonomiku a klinické výstupy (ISPOR) v Slovenskej republike

31. MEETINGS IN ASIA AND LATIN AMERICA What We Do

32. Supporting Research & Practice Globally What We Do

33. MEETINGS IN NORTH AMERICA What We Do

34. MEETING REGISTRATION: NORTH AMERICA What We Do

35. What We Do • COLLABORATION TO MOVE THE FIELD FORWARD

36. What We Do Special Interest Groups Initiated by ISPOR members, formed with a specific research-focused goal. Task Forces Formed by the Board of Directors for a specific purpose such as to develop Good Research Practices. Councils Advisory bodies to ISPOR & its Board of Directors.

37. What We Do PUBLICATIONS

38. What We Do PUBLICATIONS

39. What We Do PUBLICATIONS F u t u r e B o o k s

40. TOOLS What We Do

41. Tools For Decision-Makers What We Do • Global Health Care System Road Map • Pharmacoeconomic Guidelines Around the World • Managed Care Outcomes Research Digest • ISPOR Comments on Health Policy

42. Global Health Care Systems Road Map Overview of Country Specific Health Systems and Reimbursement Process What We Do

43. Managed Care Outcomes Research Digest Searchable by service provided, outcomes assessed or key word What We Do

44. Tools For Health Care Researchers What We Do • ISPOR Research Digest • Digest of International Databases • Good Research Practices

45. ISPOR Research Digest What We Do Electronic database ~9000 research studies from ISPOR meetings

46. Digest of International Databases Directory of Databases searchable by key attributes What We Do

47. Good Research Practices What We Do Published articles and reports on multidisciplinary topics

48. Good Research Practices What We Do Code of Ethics • Design and Research Practices • Sponsorship • Publication and Dissemination • Relationship with Others • Role of ISPOR

49. Economic/Pharmacoeconomic Methods Modeling Budget Impact Analysis CEA with Clinical Trials Drug Cost Standards Economic Data Transferability Good Research Practices What We Do

50. Good Research Practices What We Do Patient Reported Outcomes (PRO) Methods • PRO Methods and Concepts • Quality of Life Methods • Preference-based Methods • Population-based Methods • Application of Conjoint Analysis in Outcomes Research